SYNTHOMICS, INC.

Biotech · Private

DNA synthesizer instrument for high-throughput oligonucleotide synthesis with 16-fold miniaturized well geometry and real-time monitoring

Grants
$349K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
2
0 granted · 2 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · Instrumentation enabling a 16-fold decrease in oligonucleotide cost$348,950
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3185JACARANDA BIOSCIENCES, INC.——
3186TenSixteen Bio——
3187PARTEK, INC.——
3188SYNTHOMICS, INC.——
3189DISCOVERY LABORATORIES, INC.——
3190CAMINO PHARMA, LLC——
3191MABLOC, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 2
  • System And Method For Controlling Droplet Dispensingapplication
  • System And Method For Controlling Droplet Dispensingapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.